Audited results for the year ended 31 December 2019 and clinical development update

Link to Full Article Company funded through to Q4 2021 Patient recruitment for XF-73 Phase 2b trial temporarily paused due to COVID-19 pandemic Brighton, United Kingdom – 29 April 2020 – Destiny Pharma (“the Company”; AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global […]

Adherium progresses U.S. sales agreement with respiratory device U.S. market leader Monaghan Medical Corporation, a member of the Trudell Medical Group of Companies

Link to Full Article Melbourne, Australia – 29 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has signed a heads of terms sales agreement with Monaghan Medical Corporation, a US subsidiary of Trudell Medical Limited, the parent company of a multinational group of leading companies […]

Adherium announces appointment of Mr. Mike Motion as Chief Executive Officer and Ms. Anne Bell as Chief Financial Officer

Link to Full Article Melbourne, Australia – 24 April 2020: Adherium (ASX:ADR) today announced the promotion of Mr Mike Motion from Chief Operating Officer to the role of Chief Executive Officer, replacing Mr Jeremy Curnock Cook who has held the position on an interim basis. Mike will also join the Board as an Executive Director, […]

Adherium and Planet Innovation partner to develop inhaled medication adherence devices and enhanced digital software platform

Link to Full Article Melbourne, Australia – 21 April 2020: Adherium (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, today announced a strategic device hardware and software development partnership with Planet Innovation (PI). This development will enhance Adherium’s leading device coverage position in both asthma and COPD with sensors […]

Adherium announces first US disease management collaboration in COPD with HGE Health

Link to Full Article Melbourne, Australia – 16 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has agreed a US disease management collaboration with Pennsylvania-based HGE Health. Both parties will rapidly evaluate and integrate Adherium’s sensor and software technology into HGE Health’s established telemedicine platform […]

Appointment of Mr. James Ward-Lilley as a Director and Chairman

Link to Full Article 14 April 2020 – Adherium (ASX:ADR) announces that James Ward-Lilley who has been consulting to Adherium over recent months has joined the Adherium Board of Directors, and following the untimely death of Thomas Lynch, James has also been appointed Chairman of the Board. Mr. Ward-Lilley commented “I am pleased to be […]

Adherium announces death of Chairman, Thomas Lynch

Link to Full Article 8 April 2020 – Adherium (ASX:ADR) announces with considerable sadness the unfortunate and untimely death of its Chairman, Thomas Lynch. Tom had been Chairman at Adherium since joining the Board in September 2016, and the Directors and staff of Adherium send their deepest condolences to Tom’s family at this very sad […]